Medtronic (MDT) revenue breakdown
By segment, Cardiovascular is the largest at 38% of fiscal 2026 revenue; Diabetes grew fastest, 5% a year over 9 years.
By region, Rest of world is the largest at 50% of fiscal 2026 revenue, growing 3% a year over 7 years.
Revenue by segment
Fiscal years, as Medtronic reports them in its 10-K filings; fiscal 2026 total $36.3B.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $10.5B | $11.4B | $11.5B | $10.5B | $10.8B | $11.4B | $11.5B | $11.8B | $12.5B | $14.0B | 38% |
| Neuroscience | $7.4B | $7.7B | $8.2B | $7.7B | $8.2B | $8.8B | $9.0B | $9.4B | $9.8B | $10.3B | 28% |
| Medical Surgical | $9.9B | $8.7B | $8.5B | $8.4B | $8.7B | $8.5B | $8.0B | $8.4B | $8.4B | $8.8B | 24% |
| Diabetes | $1.9B | $2.1B | $2.4B | $2.4B | $2.4B | $2.3B | $2.3B | $2.5B | $2.8B | $3.1B | 9% |
| Other Operating Segments | — | — | — | — | — | $727M | $495M | $221M | $137M | $135M | 0% |
Revenue by region
Fiscal years, as Medtronic reports them in its 10-K filings; fiscal 2026 total $36.4B.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rest of world | — | — | $14.3B | $13.9B | $14.5B | $15.4B | $14.8B | $15.7B | $16.2B | $18.1B | 50% |
| United States | $16.7B | $15.9B | $16.2B | $14.9B | $15.5B | $16.1B | $16.4B | $16.6B | $17.2B | $18.1B | 50% |
| Ireland | — | — | $91M | $85M | $100M | $101M | $98M | $113M | $116M | $143M | 0% |
| Non-U.S. Developed Markets | $9.1B | $9.6B | — | — | — | — | — | — | — | — | — |
| Emerging Markets | $4.0B | $4.5B | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MDT.
Open MDT in InvestinglyQuestions
Where does Medtronic make its money?
In fiscal 2026, by segment: Cardiovascular $14.0B, Neuroscience $10.3B, Medical Surgical $8.8B, Diabetes $3.1B, Other Operating Segments $135M.
From Medtronic's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.